Effect of alirocumab on coronary plaque in patients with coronary artery disease assessed by optical coherence tomography

BACKGROUND: Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors have been demonstrated to produce significantly greater reduction in LDL cholesterol levels and cardiovascular events than standard statin therapy. However, evidence on the impact of PCSK9 inhibitors on coronary plaque comp...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Fei, Wang, Zhi Jian, Ma, Xiao Teng, Shen, Hua, Yang, Li Xia, Zhou, Yu Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8436513/
https://www.ncbi.nlm.nih.gov/pubmed/34511134
http://dx.doi.org/10.1186/s12944-021-01528-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8436513/
https://www.ncbi.nlm.nih.gov/pubmed/34511134
http://dx.doi.org/10.1186/s12944-021-01528-3

Ejemplares similares